Cohen Capital Management Inc. Has $833,000 Stake in Elanco Animal Health Incorporated (NYSE:ELAN)

Cohen Capital Management Inc. lowered its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 38.9% in the fourth quarter, HoldingsChannel.com reports. The firm owned 68,815 shares of the company’s stock after selling 43,846 shares during the quarter. Cohen Capital Management Inc.’s holdings in Elanco Animal Health were worth $833,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Commerce Bank boosted its stake in shares of Elanco Animal Health by 2.2% in the 3rd quarter. Commerce Bank now owns 35,114 shares of the company’s stock valued at $516,000 after purchasing an additional 741 shares during the last quarter. MTM Investment Management LLC boosted its stake in Elanco Animal Health by 9.3% in the fourth quarter. MTM Investment Management LLC now owns 14,168 shares of the company’s stock valued at $172,000 after acquiring an additional 1,200 shares during the last quarter. M&T Bank Corp grew its holdings in Elanco Animal Health by 5.9% during the 3rd quarter. M&T Bank Corp now owns 26,407 shares of the company’s stock worth $388,000 after acquiring an additional 1,464 shares during the period. Venturi Wealth Management LLC raised its position in shares of Elanco Animal Health by 89.9% during the 3rd quarter. Venturi Wealth Management LLC now owns 3,382 shares of the company’s stock valued at $50,000 after acquiring an additional 1,601 shares during the last quarter. Finally, Parkman Healthcare Partners LLC lifted its stake in shares of Elanco Animal Health by 1.4% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 127,812 shares of the company’s stock valued at $1,878,000 after purchasing an additional 1,770 shares during the period. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Stock Down 1.0 %

NYSE:ELAN opened at $11.02 on Friday. The stock has a 50-day simple moving average of $11.80 and a 200 day simple moving average of $13.10. Elanco Animal Health Incorporated has a 52-week low of $10.77 and a 52-week high of $18.80. The company has a market cap of $5.45 billion, a PE ratio of 27.54, a PEG ratio of 2.50 and a beta of 1.42. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on ELAN shares. Leerink Partners started coverage on Elanco Animal Health in a report on Monday, December 2nd. They issued a “market perform” rating and a $14.00 price objective for the company. UBS Group initiated coverage on shares of Elanco Animal Health in a report on Monday, December 9th. They set a “buy” rating and a $18.00 price objective for the company. Leerink Partnrs upgraded shares of Elanco Animal Health to a “hold” rating in a report on Monday, December 2nd. Barclays boosted their price target on shares of Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, November 8th. Finally, Stifel Nicolaus reduced their target price on Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Friday. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $16.00.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.